UNASSIGNED: To characterize outcomes in a cohort of adults with MS who received ICIs.
UNASSIGNED: A single-center retrospective review of medical record data was performed for people with MS treated with ICIs.
UNASSIGNED: Seven people with MS were identified, with a mean (SD) age at ICI use of 55.4 (13.7) years and a mean MS duration of 18.2 (12.2) years. Six were treated for cancer; 1 was treated for PML. After mean (SD) follow-up of 1.76 (2.15) years after ICI, outcomes are: no evidence of disease (2), residual metastatic disease (1), death due to cancer (1), death due to PML (1), and lost to follow-up (2). Notably, 0 out of 7 patients experienced an MS relapse; two out of six had new asymptomatic demyelinating magnetic resonance imaging lesions. In the three patients with expanded disability status scale (EDSS) scores at baseline and follow-up, EDSS remained stable (mean delta 0.13).
UNASSIGNED: In this cohort, no people with MS experienced clinical relapses and one-third experienced asymptomatic radiological activity following ICI treatment.
■用于表征接受ICIs的MS成人队列的结局。
■对接受ICIs治疗的MS患者的病历数据进行单中心回顾性审查。
■确定了7名MS患者,ICI使用时的平均(SD)年龄为55.4(13.7)岁,平均MS持续时间为18.2(12.2)年。6例治疗癌症;1例治疗PML。在ICI后1.76(2.15)年的平均(SD)随访后,结果是:没有疾病的证据(2),残余转移性疾病(1),癌症死亡(1)因PML死亡(1),失去了后续行动(2)。值得注意的是,7例患者中有0例出现MS复发;6例中有2例出现新的无症状性脱髓鞘磁共振成像病变。3例患者在基线和随访时的扩展残疾状况量表(EDSS)评分,EDSS保持稳定(平均Δ0.13)。
■在此队列中,在ICI治疗后,MS患者没有出现临床复发,1/3出现无症状放射性活动.